Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa)
Publication
, Conference
Muir, AJ; Srinivasan, S; Sapra, S; Dimitrova, D; Hillson, JL; Lopez-Talavera, JC
Published in: HEPATOLOGY
October 1, 2012
Duke Scholars
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2012
Volume
56
Start / End Page
578A / 579A
Location
Boston, MA
Publisher
WILEY-BLACKWELL
Conference Name
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Muir, A. J., Srinivasan, S., Sapra, S., Dimitrova, D., Hillson, J. L., & Lopez-Talavera, J. C. (2012). Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa). In HEPATOLOGY (Vol. 56, pp. 578A-579A). Boston, MA: WILEY-BLACKWELL.
Muir, Andrew J., Subasree Srinivasan, Sandhya Sapra, Dessislava Dimitrova, Jan L. Hillson, and Juan Carlos Lopez-Talavera. “Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa).” In HEPATOLOGY, 56:578A-579A. WILEY-BLACKWELL, 2012.
Muir AJ, Srinivasan S, Sapra S, Dimitrova D, Hillson JL, Lopez-Talavera JC. Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa). In: HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 578A-579A.
Muir, Andrew J., et al. “Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa).” HEPATOLOGY, vol. 56, WILEY-BLACKWELL, 2012, pp. 578A-579A.
Muir AJ, Srinivasan S, Sapra S, Dimitrova D, Hillson JL, Lopez-Talavera JC. Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa). HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 578A-579A.
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2012
Volume
56
Start / End Page
578A / 579A
Location
Boston, MA
Publisher
WILEY-BLACKWELL
Conference Name
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics